IMPORTANCE Although the long-term survival advantage of multiple arterial grafting (MAG) vs the standard use of left internal thoracic artery (LITA) supplemented by saphenous vein grafts (LITA+SVG) has been demonstrated in several observational studies, to our knowledge its safety and other long-term clinical benefits in a large, population-based cohort are unknown.
that the use of an internal thoracic artery (ITA) to the left anterior descending artery reduced 10-year mortality and late adverse cardiac events, there has been considerable interest in multiple arterial grafting (MAG) using the right internal thoracic artery (RITA), or a radial artery (RA) in addition to left ITA (LITA) for multivessel coronary artery bypass grafting (CABG) . [2] [3] [4] Although many observational studies have demonstrated the long-term survival advantages of MAG, the adoption of MAG has been slow because of the absence of randomized clinical trial evidence of long-term benefits [5] [6] [7] [8] and observational findings that were limited by single-center study populations, 9-23 noncontemporary surgical cohorts, [9] [10] [11] [19] [20] [21] small sample sizes, 9,10 or an underrepresentation of high-risk patients. 10, [18] [19] [20] [21] Moreover, conflicting or relatively little information on its safety and other clinical outcomes, such as repeated revascularization, further complicates an evaluation of the "totality of the evidence."
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A review using the Society of Thoracic Surgeons database reflected a strong reluctance toward using MAG in routine practice, 25 which was limited to fewer than 10% of patients undergoing primary CABG in 2009. Therefore, a comprehensive evaluation of the effectiveness of MAG in contemporary, routine practice is necessary, particularly in the modern era of evolving surgical techniques, advancing percutaneous coronary intervention (PCI), and improved secondary prevention. In this large, population-based study, we evaluated the safety and longterm outcomes of MAG vs the LITA supplemented by saphenous vein graft (LITA+SVG) overall and among selected subgroups of patients undergoing CABG.
Methods

Data Sources
The Cardiac Services British Columbia (BC) registry prospectively captures information on all adult heart surgical procedures, angiographies, angioplasties, and heart rhythm device procedures that are performed in BC. Coronary artery bypass grafting procedures are performed at 5 tertiary care centers. Detailed demographic data, risk factors, procedural details, and postoperative complications are entered prospectively by clinical staff members in each center. All-cause mortality until December 31, 2015, was obtained via linkage to the BC Vital Statistics. Repeated revascularization after index CABG was ascertained from the Cardiac Services BC registry for all patients. Hospitalization information between April 1, 2007, and March 31, 2015 , was obtained via linkage to the Discharge Abstract Database (DAD) that contains administrative, clinical, and demographic information on hospital discharges for acute care and day surgery in Canada. This was a retrospective study of data from the Cardiac Services BC registry, and patient information was deidentified. Approval for use of anonymized linked data with a waiver for individual consent was obtained from the University of British Columbia Research Ethics Board.
Study Population and Outcomes
Between January 1, 2000, and December 31, 2014, 24 702 adult patients older than 19 years with triple-vessel or left-main disease underwent isolated CABG in BC. The following groups of patients were excluded: 284 non-BC residents, 3143 patients who did not receive MAG or LITA+SVG (ie, SVG only, isolated LITA, RITA, or RA with SVG), 303 patients who previously underwent open-heart surgery, 616 patients who were undergoing an emergency surgery, 26 patients with prior PCI within 24 hours, and 254 patients with missing baseline covariates. The overall study cohort included 20 076 patients, with 14 496 (72.2%) receiving LITA+SVG and 5580 (27.8%) receiving MAG with or without SVG for the analyses of primary outcomes. Either bilateral internal thoracic arteries with or without RA (RITA-MAG), or LITA with RA (RA-MAG) was used among patients receiving MAG. Of the overall study cohort, 10 545 patients undergoing CABG between April 1, 2007, and December 31, 2014 , were linked to the DAD data and constituted the DAD-linked study cohort for the analyses of secondary outcomes.
The primary outcomes were all-cause mortality and repeated revascularization (ie, any subsequent PCI or CABG) following the index CABG. The secondary outcomes were postoperative myocardial infarction, heart failure, stroke, and a combined end point of all previously mentioned outcomes, including all-cause mortality and repeated revascularization. The safety outcomes included 30-day postoperative dialysis, reoperation for bleeding, and sternal reconstruction within 30 and 180 days. Definitions of secondary outcomes are provided in eAppendix 1 in the Supplement.
Statistical Analysis
We evaluated the effect of MAG vs LITA+SVG on clinical outcomes after CABG by applying 3 statistical approaches: 2 propensity score (PS) methods, PS weighting and PS matching, and multivariable Cox regression. All statistical analyses were performed in SAS, version 9.4 (SAS Institute) and R, version 3.2.4 (R Development Core Team) using the R twang package 26 for of significance was defined by a 2-tailed P value of <.05 for all statistical tests. Continuous variables were expressed as mean (SD) and compared using the t test. Categorical variables were summarized as proportions and analyzed by the χ 2 test. The cumulative incidences of mortality and the composite end point were estimated by the Kaplan-Meier method. For repeated revascularization and other secondary long-term outcomes, the cumulative incidences were estimated by the cumulative incidence functions, accounting for death as a competing risk. The median duration of follow-up was calculated based on the method of reverse All baseline covariates, including the patient demographics, clinical factors and comorbidities in the Table, and the surgical year, were incorporated in the calculation of the PS, the probability that a patient receives MAG. In PS matching, the PS was estimated from a non-parsimonious logistic model to form a sample consisting of pairs of MAG and LITA+SVG patients by the nearest-neighbor matching algorithm with a caliper of 0.2 of standard deviations of the logit of the propensityscores. In PS weighting, patients receiving MAG were assigned a weight of 1 while patients receiving LITA+SVG were assigned a weight equal to the odds of receiving MAG, the PS divided by 1 minus the PS, which was estimated by a generalized boosted model. 29 Adequacy of matching and weighting was confirmed by all baseline covariates having a standardized difference of less than 0.1. The hazard ratios (HRs) for the long-term outcomes were computed from univariable Cox regression models, and the relative risks were estimated for shortterm outcomes, with a robust variance estimator to account for the matched or weighted nature of the sample. 30 The HRs for long-term outcomes were also estimated by the multivariable Cox regression models, adjusting for baseline covariates with a P value of less than .10 retained in backward elimination. The proportional hazard assumption was confirmed for all Cox regression models. For nonfatal long-term outcomes, patients who died before experiencing these events were censored at the time of death.
We assessed the robustness of the estimated long-term MAG effects to the effect of incomplete revascularization, discharge medications (aspirin, statins, β-blockers, and angiotensin-converting enzyme inhibitor/angiotensinreceptor blockers), and surgeon effect in sensitivity analyses (eAppendix 1 in the Supplement). Although these factors may be prognostic of long-term outcomes, they were not preoperative factors to be included in the propensity-score estimation. Because surgeon effect may be highly correlated with the conduit choice, the adjustment for surgeon effect may lessen or exaggerate the true MAG effect and make interpretation of the estimated MAG effect difficult. Therefore, each of these factors was included as an additional adjustment to the PS weighting analyses to assess the robustness of the results. To address potential residual confounding, we conducted additional PS weighting analyses and tested 3 falsification end points 31 (hip fracture, pneumonia, and urinary tract infection) that were known to be related to patient condition but unlikely to be influenced by the choice of conduit.
We also conducted separate PS weighting analyses to assess MAG benefits among patient subgroups with or without diabetes, 70 years or older, impaired ejection fraction, a high body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) of 35 or more, peripheral vascular disease (PVD), chronic obstructive pulmonary disease (COPD), and renal disease. To assess whether the magnitude of the MAG effect varied across the relevant subgroups, we tested the significance of the interaction term added to the multivariable Cox regression models based on the overall study cohort.
Results
Multiple arterial grafting use increased from 29% to 36% between 2000 and 2003, declined between 2004 and 2006 , and remained around 25% thereafter (eFigure 1 in the Supplement). The median MAG use rate by surgeons was 26.5% (interquartile range [IQR] , 12.7%-46.2%).
The group who received MAG consisted of 3056 patients (54.8%) receiving RITA-MAG and 2524 patients (45.2%) receiving RA-MAG. Among patients receiving RITA-MAG, 1239 patients (40.5%) received an RA in addition to bilateral internal thoracic arteries, whereas 1817 patients (59.5%) received bilateral internal thoracic arteries. The demographic and clinical characteristics of the overall study cohort are shown in the Table. Compared with patients who received LITA+SVG, patients receiving MAG were younger, more likely to be male, and less likely to have severely impaired ejection fraction or comorbidities such as renal disease, hypertension, pulmonary hypertension, PVD, COPD, cerebrovascular disease, diabetes, anemia, and arrhythmia.
Perioperative Characteristics
The on-pump rates were comparable between the 2 groups (MAG, 95.4% vs LITA+SVG, 95.7%) . For on-pump cases, the mean (SD) pump time was 107.1 minutes (38.6) for the group receiving MAG and 101.2 minutes (32.2) for the group receiving LITA+SVG. The mean (SD) cross-clamp time was 82.5 minutes (29.8) for the group receiving MAG and 79.0 minutes (25.9) for the group receiving LITA+SVG. Single aortic cross-clamp was used among 4142 patients (77.8%) on pump in the MAG group vs 11 263 patients (81.2%) on pump in the LITA+SVG group. The proportion of incomplete revascularization was comparable (MAG, 2.0% vs LITA+SVG, 2.2%), with a mean of number of distal anastomoses of 3.9 in both groups. Conduit details are provided in eAppendix 2 in the Supplement. Both groups had similar discharge prescription rates of aspirin (MAG, 92.1% vs LITA+SVG, 91 .0%), β-blockers (MAG, 86.2% vs LITA+SVG, 82.1%) , and statins (MAG, 78.3% vs LITA+SVG, 78.1%), but not angiotensinconverting enzyme inhibitor/angiotensin-receptor blockers (MAG, 41.7% vs LITA+SVG, 51.0%).
Unadjusted Outcomes
In the overall study cohort, the median (IQR) follow-up time was 9.1 (5.1-12.6) years and 8.1 (4.5-11.7) years for the groups receiving MAG and LITA+SVG, respectively. In the DADlinked study cohort, the median (IQR) follow-up time was 4.2 (2.0-6.2) years and 4.1 (2.1-6.0) years for the groups receiving MAG and LITA+SVG, respectively. Patients receiving MAG had lower incidences of mortality, postoperative dialysis, myocardial infarction, stroke, and heart failure at 30 days (eTable 1 in the Supplement). The group receiving MAG also had lower incidences of mortality and repeated revascularization at 15 years, as well as a lower incidence of myocardial infarction, stroke, heart failure, and the composite end point at 7 years (eFigures 2 and 3 in the Supplement). More than 95% of repeated revascularization was PCI in both groups. f Renal disease is any documented history of renal disease diagnosed including dialysis, acute or chronic renal failure, or estimated glomerular filtration rate less than 60 mL/min/1.73m 2 (by the Cockcroft-Gault formula). Dialysis: patient is currently undergoing either hemodialysis or peritoneal dialysis. Failure without dialysis: acute or chronic renal failure or estimated glomerular filtration rate less than 15 mL/min/1.73m 2 without dialysis. Dysfunction estimated glomerular filtration rate between 15 and 60 mL/min/1.73m 2 .
g Moderate/severe anemia is defined as hemoglobin level less than 11 g/dL.
Adjusted Outcomes
Standardized differences less than 0.1 for all covariates in PS weighting (Table) and PS matching indicated balance between the 2 groups (eTable 2 in the Supplement). The results that were obtained from the PS weighting analyses are presented in this section and the results from the PS matching and multivariable Cox regression analyses are provided in eTables 3-9 in the Supplement.
Long-term Outcomes
Compared with LITA+SVG, MAG was associated with a 21% reduction in mortality (hazard ratio [HR] , 0.79; 95% CI, 0.72-0.87), and a 26% reduction in repeated revascularization (HR, 0.74; 95% CI, 0.66-0.84) in 15-year follow-up ( Figure 1 ). The incidences of myocardial infarction, heart failure, and the composite end point of all long-term outcomes in 7-year follow-up were also significantly lower in the group receiving MAG, whereas the incidence of stroke was comparable in both groups (eFigure 4 in the Supplement).
Multiple arterial grafting was associated with a significantly lower mortality rate regardless of the presence of diabetes, obesity (BMI ≥ 35), or renal disease. Multiple arterial grafting was associated with a significantly lower mortality rate among patients with moderately impaired ejection fraction (35%-50%), but not among patients with a severely impaired ejection fraction of less than 35%. A reduced risk of mortality with MAG, although statistically nonsignificant, was observed in the subgroups who were 70 years or older or had PVD or COPD. The relative mortality reduction that was associated with MAG was significantly smaller in subgroups with an ejection fraction of less than 35%, 70 years or older, or PVD, as indicated by significant P values from interaction tests (Figure 2 ). Multiple arterial grafting was associated with a lower repeated revascularization rate in all subgroups except for those with an ejection fraction of less than 35% and those who were 70 years or older (Figure 3 ). Adjusted cumulative incidence curves for mortality and repeated revascularization for each subgroup are provided in eFigures 5-11 in the Supplement. A-C, The adjusted cumulative incidences for mortality and repeated revascularization were estimated by incorporating weights that were obtained from propensity score (PS) weighting for the overall study cohort (LITA+SVG, n = 14496; MAG, n = 5580) at the end of 15-year follow-up. The adjusted cumulative incidences for myocardial infarction, stroke, heart failure, and the composite end point were estimated by incorporating weights that were obtained from PS weighting for the Discharge Abstract Database (DAD)-linked study cohort (LITA+SVG, n = 7912; MAG, n = 2633) at the end of 7-year follow-up. Cumulative incidences of mortality and the composite end point were estimated by the Kaplan-Meier method. For nonfatal long-term outcomes, cumulative incidences were estimated by the cumulative incidence function accounting for death as a competing risk. Adjusted hazard ratios were estimated from univariable Cox regression models that incorporated weights that were obtained from PS weighting. P values were calculated using the weighted Wald χ 2 test. B and C, The number of patients at risk was calculated by incorporating weights that were obtained from PS weighting (ie, weight of 1 for patients in the group receiving MAG and a weight equal to the odds of receiving MAG for patients in the group receiving LITA+SVG) and rounded to the nearest integer for the group receiving LITA+SVG.
Short-term Outcomes
The incidences of mortality, repeated revascularization, and all safety outcomes were comparable between the 2 groups except for sternal reconstruction within 180 days (Figure 4) . A further analysis that compared the sternal reconstruction rates between RITA-MAG and RA-MAG demonstrated that the rate was significantly higher among patients who received RITA-MAG than RA-MAG at both 30 days (1.5% vs 0.4%, P = .002) and 180 days (2.5% vs 0.6%, P < .001). All short-term outcome rates were not significantly higher with MAG compared with LITA+SVG within all high-risk subgroups (eTables 10-16 in the Supplement).
Sensitivity Analyses and Falsification End Point Tests
The magnitude of long-term MAG benefits remained similar after the adjustment for the effect of incomplete revascularization or discharge medications. A further adjustment for surgeon effect did not lessen the MAG benefits in improving longterm survival rates and reducing the incidences of myocardial infarction and heart failure. The advantage of MAG in reducing repeated revascularization rates was moderately attenuated but remained statistically significant (eTable 17 in the Supplement). The falsification tests showed no significant association between the use of MAG and any of the falsification end points (eTable 18 in the Supplement).
Discussion
Our study is unique in undertaking a comprehensive evaluation of short-and long-term clinical outcomes after CABG in a population-based cohort consisting of 5580 patients who received MAG (27.8%) and 14 496 patients who received LITA+SVG (72.2%). The broad application of MAG using the additional arterial conduit of either the RITA or RA enabled us to evaluate the benefit of MAG in a representative population of patients who were undergoing CABG and address its differential benefits among subgroups. The effect of treatment selection bias and potential confounders in estimating the benefits of MAG was minimized by adjusting for patient demographics, clinical risk factors, comorbidities, and the year of surgery using 3 rigorous statistical adjustment techniques. The long-term MAG benefits in reducing mortality rates and the incidences of repeated revascularization, myocardial infarction, and heart failure were similar across all 3 methods (eTable 9 in the Supplement). The sensitivity analyses demonstrated that the significant long-term benefits of MAG were not qualitatively affected by incomplete revascularization, discharge medications, or surgeon effect. The potential residual confounding was explored by falsification end points.
In 2016, the Arterial Revascularization Trial, a large multicenter randomized clinical trial that compared survival and clinical outcomes between RITA-MAG and single ITA, showed no clinical benefit of RITA-MAG at 5 years.
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The possible reasons for the midterm findings were discussed by the authors and other investigators. 7, [32] [33] [34] Despite the absence of randomized clinical trial evidence of longterm clinical benefits of MAG, long-term survival advantages of RITA-MAG over LITA+SVG have been consistently reported in many observational studies [9] [10] [11] [18] [19] [20] [21] [22] 35 and Adjusted hazard ratios were estimated from univariable Cox regression models that incorporated weights that were obtained from propensity score (PS) weighting for each subgroup of the overall study cohort. P values were calculated based on the Wald χ 2 test for an interaction term included in a multivariable Cox regression model using the overall study cohort, adjusting for significant baseline covariates with a P value of <.1 that was retained in backward elimination. BMI indicates body mass index (calculated as weight in kilograms divided by height in meters squared); COPD, chronic obstructive pulmonary disease; EF, ejection fraction; PVD, peripheral vascular disease; Renal disease, dialysis, acute, or chronic renal failure, or estimated glomerular filtration rate of less than 60 L/min/1.73 m 2 .
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Long-term Outcomes of Multiple Arterial Coronary Artery Bypass Grafting meta-analyses that reported a 19% to 22% mortality reduction. [36] [37] [38] Similarly, the survival benefits of RA-MAG were reported in studies from 2 institutions that endorsed liberal RA use. 15-17 A 21% reduction in late mortality was reported by Locker and colleagues 13 in a 15-year study that incorporated both RITA-MAG and RA-MAG. We also observed an equivalent survival benefit of MAG with a more frequent use of RA-MAG, 45.2% in our cohort compared with 14.2% in their study. The consistent survival benefit of MAG observed across these studies, regardless of which second arterial conduit was predominantly used, suggests that both RITA and RA can achieve a similar survival benefit, which is also supported by other recent studies. 34, 39, 40 Contrary to the consistent survival benefits of MAG that were shown in observational studies, the effect of MAG on other clinical outcomes has been inconsistent or limited in previous reports. Some studies found reduced incidences of both PCI and CABG individually 19 or as combined repeated revascularization 23 among patients receiving RITA-MAG, whereas the significant benefits of RITA-MAG were limited to reducing subsequent CABG, but not PCI, in other studies. 9,21 Guruetal 41 did not find any significant advantage of MAG over single arterial grafting in reducing repeated revascularization rates, in a mean follow-up of less than 5 years. Little information exists on the effectiveness of RA-MAG on reducing repeated revascularization rates. Although a single-center study found its potential benefits by comparing the frequency of patients returning to the institution for catheterization, the authors acknowledged the underestimation of the actual repeated revascularization need in their study. 16 By contrast, the ascertainment of repeated revascularization from the provincial clinical registry in our study provided a more accurate estimation of the need for repeated revascularization. We observed a 26% reduction in repeated revascularization with MAG compared with LITA+SVG, with the cumulative incidence curves separating early and continuing to diverge to 15 years ( Figure 1 ). Moreover, MAG was also associated with significantly reduced incidences of myocardial infarction and heart failure, consistent with previous studies. 9, 19, 21, 41 Given the complex decision making in optimizing surgical strategy, identifying the appropriate candidates for MAG is crucial to maximize its long-term benefits. We demonstrated a consistent long-term survival benefit and reduced need for repeated revascularization among diabetic patients. Furthermore, we observed a greater absolute mortality rate reduction among patients with diabetes compared with patients without diabetes at 15 years (9.5% vs 3.8%, eFigure 5 in the Supplement). Similarly, MAG was associated with clear long-term advantages in reducing both mortality and repeated revascularization rates among both patients who were and were not obese, which supports existing evidence.
48,49 Adjusted hazard ratios were estimated from univariable Cox regression models that incorporated weights that were obtained from propensity score (PS) weighting for each subgroup of the overall study cohort. P values were calculated based on the Wald χ 2 test for an interaction term included in a multivariable Cox regression model using the overall study cohort, adjusting for significant baseline covariates with a P value of <.1 that was retained in backward elimination. BMI indicates body mass index (calculated as weight in kilograms divided by height in meters squared); COPD, chronic obstructive pulmonary disease; EF, ejection fraction; PVD, peripheral vascular disease; Renal disease, dialysis, acute, or chronic renal failure, or estimated glomerular filtration rate of less than 60 mL/min/1.73 m 2 .
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To our knowledge, no recent studies have examined the long-term effect of MAG among patients with renal disease, COPD, or PVD. The MAG benefits in reducing both mortality and repeated revascularization rates were consistent regardless of the presence of renal disease. A greater reduction in repeated revascularization rates and a reduced survival benefit were observed among patients with COPD or PVD. Compared with younger patients, the survival benefit among elderly patients was significantly reduced in our study; however, an 11% reduction in mortality of borderline statistical significance supports the MAG benefits that were reported in 3 studies 50-52 but conflicts with other studies. 40, 53, 54 The current evidence of MAG benefits is robust for patients with moderately impaired ejection fraction 19, 20, 42, 55 but conflicting for patients with severely impaired ejection fraction. Our finding of no survival benefit for patients with an ejection fraction of less than 35% is consistent with those 2 RITA-MAG studies 42,56 but differs from 1 RA-MAG study.
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Lytle et al 20 suggested that heterogeneous mortality risks across patient spectrums were the underlying mechanism for differential MAG effects. Superior long-term patency of the second arterial conduit may translate into improved clinical outcomes, but its influence must be strong enough to offset the influences of risk factors that limit survival after CABG. 20,57 Therefore, a loss of MAG benefits among patients with severely impaired ejection fraction is likely related to the influence of severe left ventricular dysfunction and other noncardiac comorbidities on survival, as discussed in other studies. 42, 56 Analogously, a moderated benefit of MAG among elderly patients supports this inference because of diminished life expectancy and more comorbidities. 40, 53 Nevertheless, a survival benefit greater than 10% was observed for most of the subgroups, demonstrating that a potential MAG benefit can be realizable, even among high-risk patient subgroups.
Perceived concerns regarding increased perioperative mortality and morbidity, particularly sternal wound complications associated with RITA-MAG, have limited its use to a small proportion of patients undergoing CABG. 36 We observed similar incidences of adverse events at 30 days for the groups receiving MAG and LITA+SVG but a significantly higher risk of sternal reconstruction at 180 days in the group receiving MAG, although the absolute increase was small (MAG, 1.9% vs LITA+SVG, 1.1%; P = .02). Our findings are consistent with those of the Arterial Revascularization Trial that reported similar 30-day adverse outcomes between the 2 groups and a higher incidence of sternal reconstruction associated with RITA-MAG at 6 weeks from randomization (RITA-MAG, 1.9% vs single ITA, 0.6%). 6 Furthermore, we confirmed that RA-MAG was associated with a significantly lower risk of sternal reconstruction than RITA-MAG at 180 days (0.6% vs 2.5%, P < .001), which corroborated findings from another study. 58 Among all high-risk subgroups, MAG was not associated with significantly higher incidences of 30-day adverse events. Nevertheless, a higher likelihood of sternal reconstruction at 180 days with MAG, although statistically nonsignificant, among elderly patients or patients with diabetes, PVD, or obesity suggests a need for incorporating strategies to mitigate sternal wound complications in considering MAG for these patients (eTables 12-18 in the Supplement).
Limitations
Our results should be interpreted in the context of the inherent limitations of observational studies. We attempted to minimize treatment selection bias by using rigorous statistical adjustment techniques; however, there remains the possibility of potential bias because of unmeasured confounders. The choice of a specific revascularization strategy for a patient is often subjective and may be affected Adjusted cumulative incidences and relative risks for 30-day mortality, 30-day repeated revascularization, 30-day reoperation for bleeding, and in-hospital postoperative dialysis were estimated by incorporating weights that were obtained from propensity score (PS) weighting from the overall study cohort (LITA+SVG, n = 14496; MAG, n = 5580). Adjusted cumulative incidences and relative risks for 30-day myocardial infarction, stroke, and heart failure were estimated incorporating weights obtained from PS weighting from the Discharge Abstract Database (DAD)-linked study cohort (LITA+SVG, n = 7912; MAG, n = 2633). Adjusted cumulative incidences and relative risks for 30-day and 180-day sternal reconstruction were estimated by incorporating weights that were obtained from PS weighting from a subset of patients in the DAD-linked study cohort who were undergoing CABG from April 1, 2007, to September 30, 2014 (LITA+SVG, n = 7614; MAG, n = 2544). Adjusted relative risks and P values from the χ 2 tests were calculated by incorporating weights that were obtained from PS weighting.
by factors that are prognostically important but unavailable in the data. Subtle factors, such as the size and quality of coronary targets and patient frailty, are unmeasured but important for a surgeon's choice of revascularization strategy and may influence clinical outcomes. 36, 59 Nevertheless, the absence of an association between MAG and the falsification end points suggests that patients who received MAG were not systematically healthier after adjustment. Therefore, the observed MAG benefit is less likely to be owing to residual confounding.
Conclusions
Compared with LITA+SVG, MAG is associated with reduced incidences of mortality, repeated revascularization, myocardial infarction, and heart failure among patients with multivessel disease who are undergoing CABG without increased incidences of mortality or other adverse events at 30 days. The long-term benefits consistently observed across multiple outcomes and subgroups support the consideration of MAG for a broader spectrum of patients. 
ARTICLE INFORMATION
I. Definitions
Moderate/Severe anemia: Preoperative hemoglobin < 110 g/L Multi-vessel disease: Extent of stenosis ≥50% in three vessels or in left main
Renal disease: Patient has any documented history of renal disease diagnosed including dialysis, acute or chronic renal failure, or estimated glomerular filtration rate (GFR) < 60 (by the Cockcroft-Gault formula)
• Dialysis -patient is currently undergoing either hemodialysis or peritoneal dialysis • Failure without dialysis -Acute or chronic renal failure or estimated GFR<15 without dialysis • Dysfunction -15 ≤ estimated GFR < 60
Urgent status: Any instances when the patient had left main stenosis >70%, unstable angina on intravenous nitroglycerin/heparin drip Incomplete revascularization: number of distal anastomoses less than the number of diseased vessels; left main disease was categorized as double-vessel disease except when in combination with 70% or higher right coronary artery stenosis, in which case it was categorized as triple-vessel disease
Secondary Outcomes
For the definition of a secondary outcome based on the diagnosis and procedure codes in the Discharge Abstract Data (DAD), an episode of care is defined as all contiguous hospitalizations including transfers to another acute care institution or same surgery visit occurring within a day of discharge from the previous acute care hospitalization or same-day surgery visit. The post-operative complications were found in the discharge summary in the Cardiac Services British Columbia (CSBC) registry.
Myocardial-infarction: Any of the following three conditions
• Post-operative myocardial-infarction complication recorded in the CSBC registry • Post-operative myocardial-infarction complication identified from the DAD:
o ICD-10 Code: I21 or I22 and o Diagnosis Type: 2 (Post-admit comorbidity) identified from the DAD during the hospitalization for the index CABG or during the subsequent hospitalizations within the same episode of care.
• A subsequent hospital admission for myocardial-infarction following discharge from the episode of care for index CABG o ICD-10 Code: I21 or I22 and o Diagnosis Type: All Diagnosis Types except Diagnosis Type 2 (Post-admit comorbidity)
Heart-failure: Any of the following three conditions 
II. Conduit Details
Internal thoracic artery (ITA) grafts were predominately harvested with a pedicle. Among 20,076 patients included in the overall study cohort, 19,975 patients (99.5%) had complete distal anastomotic information. Among 5580 patients receiving MAG, 1730 patients (31%) received all-arterial grafting and 3850 patients (69%) received multiple arterial grafting supplemented by saphenous vein graft (SVG).
Among the 19,975 patients receiving a left internal thoracic artery (LITA) graft, 95.8% were in-situ, 93.0% were anastomosed to a single distal artery, and 7.0% were used as sequential anastomoses. The single distal anastomosis was grafted to the left anterior descending artery (LAD) in 90.7%, to the left circumflex (LCX) region in 6.4%, and to other arteries in 2.9%. Of the sequential LITA grafts, 69.3% were grafted to the LAD-diagonal territory, 30.3% to LCX, and 0.4% to other arteries. Overall, the LITA was anastomosed almost exclusively to the left-sided coronary arteries, 89.1% to the LAD territory and 8.1% to the LCX territory.
Among the 3,051 patients receiving a right internal thoracic artery (RITA) graft, 90.2% were in-situ, 93.2% were anastomosed to a single distal artery, 4.6% were performed sequentially, and 2.2% were Y-grafts. Of the single distal anastomoses, 54.4% were grafted to the LAD, 27.4% to the right coronary artery (RCA), 11.7% to the LCX, and 6.4% to other arteries. Of the sequential RITA grafts, 55.4% were grafted to the LAD-diagonal territory, 18.0% to the LCX and diagonal, 11.5% to the LCX and the ramus intermedius coronary artery (Ramus), 7.2% to the LCX and RCA, 6.5% to the RCA and 1.4% to other arteries. Overall, the most frequently grafted territory for the RITA was the LAD territory (54.0%), followed by the RCA territory (26.0%) and the LCX territory (14.0%).
For radial arteries (RAs), 3,790 distal anastomoses were performed in 3,699 patients, of which 60.7% were anastomosed to a single distal artery, 36.7% were performed sequentially, and 2.6% were y-grafted. Among the single RA distal anastomoses, 49.2% were grafted to the LCX, 40.7% to RCA, 5.7% to Ramus, 4.4% to others. Among the sequential RA grafts, 31.0% were grafted to the LCX and diagonal, 24.5% to the LCX, 16.4% to the LCX and Ramus, 15.4% to the RCA, 5.8% to the LCX and the RCA, and 7.0% to other territories. Overall, the two most frequently grafted territories for RA grafts were the LCX (60.5%) and the RCA (30.9%) territories.
Using saphenous veins, 34,508 distal anastomoses were performed in 18,325 patients, of which 67.5% were anastomosed to a single distal artery, 31.7% performed sequentially, and 0.8% y-grafts. Overall, the most two frequently grafted territories of SVG were the LCX (42.7%) and the RCA (41.2%) territories. Based on 10545 patients contained in DAD-linked cohort (LITA+SVG, N=7912; MAG, N=2633). Cumulative incidences of the combined outcome of mortality, repeat-revascularization, myocardial-infarction, heart-failure, and stroke were estimated by the Kaplan-Meier method. Cumulative incidences of non-fatal outcomes were estimated by the cumulative incidence function accounting for death as a competing risk. Based on 10545 patients contained in DAD-linked cohort (LITA+SVG, N=7912; MAG, N=2633). Cumulative incidences of the combined outcome of mortality, repeat-revascularization, myocardial-infarction, heart-failure, and stroke were estimated by the Kaplan-Meier method. Cumulative incidences of non-fatal outcomes were estimated by the cumulative incidence function accounting for death as a competing risk.
III. Figures
a The number of patients at risk was calculated incorporating weights obtained from PS-weighting (i.e. weight of 1 for patients in the MAG group and a weight equal to the odds of receiving MAG for patients in the LITA+SVG group) and rounded to the nearest integer for the LITA+SVG group. c Incomplete revascularization was defined as the number of distal anastomoses less than the number of diseased vessels.
d Discharge medications included aspirin, statins, beta-blockers, and angiotensin-converting-enzyme-inhibitors/angiotensinreceptor-blockers
